Using a new imaging method to detect heart damage from cancer treatments
[18F]F-AraG as an imaging biomarker for early diagnosis and monitoring of cardiotoxicity related to doxorubicin and immune check point inhibitor therapy
This study is looking at a new way to use special imaging to spot early heart problems in cancer patients who are receiving treatments like doxorubicin and immune checkpoint inhibitors, so doctors can catch any issues early and help keep your heart healthy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11004626 on NIH RePORTER |
What this research studies
This research focuses on developing a noninvasive imaging technique to identify early signs of heart damage caused by cancer therapies, particularly doxorubicin and immune checkpoint inhibitors. By utilizing positron emission tomography (PET) with a specific imaging agent, the study aims to improve the detection of cardiotoxicity before it becomes severe. This approach could help doctors monitor heart health in cancer patients more effectively and allow for timely interventions to prevent serious complications. The research addresses a critical gap in current monitoring methods, which often fail to detect early cardiac issues.
Who could benefit from this research
Good fit: Ideal candidates for this research are cancer patients undergoing treatment with doxorubicin or immune checkpoint inhibitors who may be at risk for heart damage.
Not a fit: Patients who are not receiving cancer treatments that are known to cause cardiotoxicity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier diagnosis and better management of heart complications in cancer patients, ultimately improving their quality of life.
How similar studies have performed: Previous research has shown promise in using advanced imaging techniques to detect cardiac issues in cancer patients, suggesting that this approach could be effective.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Seo, Youngho — University of California, San Francisco
- Study coordinator: Seo, Youngho
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.